QuickBird Medical
  • German
  • Case Studies
    • Case Studies
    • Customers
  • Services
    • Development: DiGA
    • Development: Medical Software – EU & MDR
    • Development: Medical Software – US & FDA
    • Embedded Software
    • Development: Wearables for Medical Devices
    • Development: Decision Support Systems
    • Development: Medical AI Systems
    • Legal Manufacturer for Medical Devices
    • Further Services
  • Insights
  • About Us
    • Company
    • Team
    • Jobs
    • Certifications
  • Contact
Select Page
← to the overview of all news

AI Act: Ban on Prohibited Practices Takes Effect

February 12, 2025

The AI Act is entering into force in stages: since February 2, the use of prohibited practices has been ruled out. What exactly these prohibited practices are is explained by the EU Commission across 140 pages of guidelines.

AI Act - What Happens Next

If you are interested in the AI Act, also read our updated expert article: AI Act: A Guide for Medical Device Manufacturers under the MDR (2025).


Sie planen die Umsetzung einer Medical Software
oder DiGA?

Kontaktieren Sie uns für ein kostenloses Erstgespräch. Wir geben Ihnen eine Einschätzung zu Aufwand und Zeitrahmen für die Umsetzung Ihres Vorhabens. Dabei prüfen wir auch die regulatorischen und strategischen Rahmenbedingungen für Ihr Produkt.

Kontakt aufnehmen

Are you planning to develop medical software
or a DiGA?

Contact us for a free initial consultation. We’ll give you an estimate of the effort and timeline required to bring your project to life. We’ll also review the regulatory and strategic considerations for your product.

Contact Us
Kontakt

+49 (0) 89 54998380
kontakt@quickbirdmedical.com

 

Whitepaper

13 wichtige Empfehlungen für angehende DiGA-Hersteller 2026

13 wichtige Empfehlungen für angehende Software-Medizinprodukt-Hersteller 2026

Aktuelles

Medical Software- und DiGA-Newsletter

Digital Health Events 2026

Presse – QuickBird in den Medien

© 2026 Impressum | Datenschutz